Takeda Pharmaceutical Co ADRTAK
Price$17.86Intrinsic value$6.8961% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $30.6B+8.4% YoYTTM through 31 Mar 2025
Net Income $720M-24.4% YoYTTM through 31 Mar 2025
Free Cash Flow $5.7BTTM through 31 Mar 2025

Margins

Current
EBITDA Margin24.1%
Operating Margin7.5%
Net Margin2.4%

Returns

1.6%ROE
0.8%ROA

Balance Sheet Health

Current Ratio1.01x
Cash & Equivalents$385.1B

Quality Metrics

Piotroski F-Score4 / 9
FCF Margin18.7%
Rule of 4020.9

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $4.6T
Diluted EPS
'19'20'21'22'23'24'25
FY2025: $67.23

Dividend

$0.34Per share, FY20251.79%Yield

Capital Allocation

Capex Intensity657.0%
Financials converted at 149.9130 from JPY.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.